We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights NVIDIA, Visa, Amgen, Chubb and PACCAR
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 29, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. (NVDA - Free Report) , Visa Inc. (V - Free Report) , Amgen Inc. (AMGN - Free Report) , Chubb Ltd. (CB - Free Report) and PACCAR Inc (PCAR - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for NVIDIA, Visa and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Visa Inc. and Amgen Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
NVIDIA's shares have outperformed the Zacks Semiconductor - General industry over the past year (+239.1% vs. +164.8%). The company's Computer & Networking revenues are gaining from the strong growth of artificial intelligence (AI), high-performance computing and accelerated computing.
The data center end-market business is likely to benefit from the growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA Hopper and Ampere architectures. A surge in hyperscale demand and a solid uptake of AI-based smart cockpit infotainment solutions are acting as tailwinds.
Collaborations with Mercedes-Benz and Audi are likely to advance its presence in autonomous vehicles and other automotive electronics space. However, its near-term prospects are likely to be hurt by softening IT spending amid macroeconomic headwinds.
Shares of Visa have outperformed the Zacks Financial Transaction Services industry over the past year (+29.8% vs. +25.2%). The company's strategic acquisitions and alliances are fostering long-term growth and consistently driving its revenues. It expects net revenues to increase in the low double digits for fiscal 2024.
Visa, fueled by increased payments and sustained investments in technology, is witnessing bottom-line growth. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
The company beat earnings estimates by 3.4% in the fiscal first quarter of 2024. However, elevated operating expenses pose margin challenges. Additionally, it is witnessing a declining cash volume from the Asia-Pacific and CEMEA regions. As such, the stock warrants a cautious stance.
Amgen's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+24.3% vs. -4.5%). The company expects strong sales growth of products like Tezspire, Evenity, Repatha, Prolia and Tavneos to be offset by lower revenues from oncology biosimilars and legacy established products such as Enbrel in the future quarters.
The addition of Horizon Therapeutics has given Amgen a significant rare disease business. Amgen also has some key pipeline assets in obesity and inflammation, which are indications that can have a large market opportunity. Several data readouts are expected in the next 12 months.
However, increased pricing headwinds and competitive pressure are hurting sales of many products, including some biosimilars. Weakness in some key brands like Otezla and Lumakras create potential revenue headwinds. Estimates have gone up ahead of Q4 earnings release. Amgen has positive record of earnings surprises in recent quarters.
Other noteworthy reports we are featuring today include Chubb Ltd. and PACCAR Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights NVIDIA, Visa, Amgen, Chubb and PACCAR
For Immediate Release
Chicago, IL – February 29, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp. (NVDA - Free Report) , Visa Inc. (V - Free Report) , Amgen Inc. (AMGN - Free Report) , Chubb Ltd. (CB - Free Report) and PACCAR Inc (PCAR - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for NVIDIA, Visa and Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., Visa Inc. and Amgen Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
NVIDIA's shares have outperformed the Zacks Semiconductor - General industry over the past year (+239.1% vs. +164.8%). The company's Computer & Networking revenues are gaining from the strong growth of artificial intelligence (AI), high-performance computing and accelerated computing.
The data center end-market business is likely to benefit from the growing demand for generative AI and large language models using graphic processing units (GPUs) based on NVIDIA Hopper and Ampere architectures. A surge in hyperscale demand and a solid uptake of AI-based smart cockpit infotainment solutions are acting as tailwinds.
Collaborations with Mercedes-Benz and Audi are likely to advance its presence in autonomous vehicles and other automotive electronics space. However, its near-term prospects are likely to be hurt by softening IT spending amid macroeconomic headwinds.
(You can read the full research report on NVIDIA here >>>)
Shares of Visa have outperformed the Zacks Financial Transaction Services industry over the past year (+29.8% vs. +25.2%). The company's strategic acquisitions and alliances are fostering long-term growth and consistently driving its revenues. It expects net revenues to increase in the low double digits for fiscal 2024.
Visa, fueled by increased payments and sustained investments in technology, is witnessing bottom-line growth. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value.
The company beat earnings estimates by 3.4% in the fiscal first quarter of 2024. However, elevated operating expenses pose margin challenges. Additionally, it is witnessing a declining cash volume from the Asia-Pacific and CEMEA regions. As such, the stock warrants a cautious stance.
(You can read the full research report on Visa here >>>)
Amgen's shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+24.3% vs. -4.5%). The company expects strong sales growth of products like Tezspire, Evenity, Repatha, Prolia and Tavneos to be offset by lower revenues from oncology biosimilars and legacy established products such as Enbrel in the future quarters.
The addition of Horizon Therapeutics has given Amgen a significant rare disease business. Amgen also has some key pipeline assets in obesity and inflammation, which are indications that can have a large market opportunity. Several data readouts are expected in the next 12 months.
However, increased pricing headwinds and competitive pressure are hurting sales of many products, including some biosimilars. Weakness in some key brands like Otezla and Lumakras create potential revenue headwinds. Estimates have gone up ahead of Q4 earnings release. Amgen has positive record of earnings surprises in recent quarters.
(You can read the full research report on Amgen here >>>)
Other noteworthy reports we are featuring today include Chubb Ltd. and PACCAR Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.